Form D · Biotechnology

BIODESIX INC

Boulder, CO · CIK 0001439725

Offering snapshot reported Oct 1, 2020 · SEC filing

Reported sold
$16M
Offering amount: $31M
Investors reported
32
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Dec 10, 2019
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$8M$16MDec 20, 2019: $3,041,529.00Dec 20, 2019Oct 1, 2020: $16,000,000.00Oct 1, 2020

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$3,041,529 → $16,000,000
  • Reported investors27 → 32

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Oct 1, 2020Amendment$16,000,000$12,958,471vs Dec 20, 201932SEC filing
Dec 20, 2019Initial$3,041,529No comparison27SEC filing
Aug 22, 2019Initial$4,902,500No comparison26SEC filing
Oct 23, 2018Initial$17,511,736No comparison33SEC filing
Jul 18, 2018Amendment$7,987,428$0vs Jul 16, 20181SEC filing
Jul 16, 2018Initial$7,987,428No comparison1SEC filing
May 8, 2018Initial$5,282,162No comparison22SEC filing
Mar 9, 2018Initial$1,500,000No comparison1SEC filing
Apr 24, 2017Initial$13,165,482No comparison17SEC filing
Nov 30, 2016Initial$5,121,632No comparison12SEC filing
Jul 27, 2016Initial$6,114,729No comparison15SEC filing
Feb 12, 2016Initial$17,756,512No comparison24SEC filing
Oct 8, 2015Initial$8,609,000No comparison18SEC filing
Jun 23, 2015Initial$10,390,000No comparison24SEC filing
Jan 13, 2015Initial$11,285,000No comparison19SEC filing
Jan 13, 2014Amendment$14,407,686$6,085,896vs Dec 3, 201326SEC filing
Dec 3, 2013Initial$8,321,790No comparison24SEC filing
Oct 22, 2013Initial$4,011,400No comparison21SEC filing
Apr 11, 2013Initial$7,313,440No comparison23SEC filing
Sep 4, 2012Initial$5,685,500No comparison11SEC filing
Jul 5, 2011Initial$10,000,000No comparison13SEC filing
Oct 28, 2010Initial$3,536,232No comparison16SEC filing
Oct 23, 2009Amendment$4,799,980$299,980vs Sep 28, 200912SEC filing
Sep 28, 2009Initial$4,500,000No comparison3SEC filing
Sep 2, 2008PaperNot reportedNo comparisonNot reportedSEC filing
Sep 2, 2008PaperNot reportedNo comparisonNot reportedSEC filing
Sep 2, 2008PaperNot reportedNo comparisonNot reportedSEC filing
Sep 2, 2008PaperNot reportedNo comparisonNot reportedSEC filing
Sep 2, 2008PaperNot reportedNo comparisonNot reportedSEC filing
Jul 8, 2008PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Other
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-356180
Convertible Promissory Note and the equity securities issuable upon conversion of such Note

Source: Form D, filed Oct 1, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Paul Beresford, Ph.D. Executive
Wendy Blosser Executive
David Brunel Director
Robert Cawthorn Director
Bobbi Coffin Executive
Robin Cowie Executive
Liz Fliegelman Executive
Jean Franchi Director
Robert Georgantas Executive
Scott Hutton Director, Executive
Hany Massarany Director
Mark Miller Director
John Patience Director
Gary Pestano, Ph.D. Executive
Jim Purvis Executive
Heinrich Roder Director, Executive
Heinrich Roder, D.Phil Executive
Heinrich Roder, D.Phil. Executive
Frank Ronchetti Executive
Jack Schuler Director
Matt Stauffer Executive
Matthew Strobeck Director
Linda Traylor, Ph.D. Executive
Charles Watts Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
2970 Wilderness Place Suite 100
Boulder, CO, 80301